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Abstract  
Itraconazole (ITR) is an antifungal drug with a limited bioavailability due to its poor aqueous 
solubility. In this study, ITR was used to investigate the impact of nanonisation and solid state 
change on drug’s apparent solubility and dissolution. A bottom up approach to the production 
of amorphous ITR nanoparticles (NPs), composed of 100% drug, with a particle diameter below 15 
250 nm, using heat induced evaporative antisolvent nanoprecipitation (HIEAN) from acetone 
was developed. The NPs demonstrated improved solubility and dissolution in simulated gastro-
intestinal conditions when compared to amorphous ITR microparticles. NPs produced with 
polyethylene glycol (PEG) or its methoxylated derivative (MPEG) as a stabiliser enabled the 
production of smaller NPs with narrower particle size distribution and enhanced apparent 20 
solubility. MPEG stabilised NPs gave the greatest ITR supersaturation levels (up to 11.6 ± 0.5 
µg/ml) in simulated gastric fluids. The stabilising polymer was in an amorphous state. Dynamic 
vapour sorption data indicated no solid state changes in NP samples with water vapour at 25 °C, 
while crystallisation was apparent at 50 °C. HIEAN proved to be an efficient method of 
production of amorphous ITR NPs, with or without addition of a polymeric stabiliser, with 25 
enhanced pharmaceutical properties.         
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1. Introduction 
The increasing frequency of drug candidates with complex molecular structure and limited 30 
aqueous solubility is a major challenge to the pharmaceutical industry. The poor solubility of 
these drugs in the gastro-intestinal fluid is a substantial hurdle to their oral administration. 
Many therapeutically active compounds exhibiting dissolution rate-limited bioavailability fail 
commercialisation, which endeavours scientists to establish a number of strategies to improve 
the solubility and subsequent bioavailability of such drugs (Dressman et al. 2000, Gardner et al. 35 
2004). Production of nanoparticles (NPs) is one of the commonly investigated approaches to 
improve the performance of drugs that possess high permeability but poor solubility (BSC class 
II drugs) and are likely to have dissolution-limited absorption rates. The breakdown of bulk 
material into particles in the nanometre range leads to a significant increase in the surface area 
and thus an improvement in dissolution rates (Liversidge et al. 1992).  40 
Itraconazole (ITR) is a BCS class II drug with aqueous solubility of less than 1 µg/ml (Matteucci 
et al. 2009), which has been extensively used as a model drug to study the potential advantages 
of nanonisation. It is an azole antifungal agent, which is effective against a variety of fungal 
species such as Aspergillus, Cryptococcus, candida, Blastomyces, and Histoplasma capsulatum 
var. capsulatum (Odds et al. 2000, Saag and Dismukes 1988). However, the use of ITR is limited 45 
owing to its poor bioavailability and variable absorption (Kapsi and Ayres 2001) where the oral 
solid dosage form available on the market (Sporanox®) has an absolute bioavailability of 30% 
(Barrett et al. 2008).  
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A wide variety of techniques have been used to form ITR NPs. The top down approach is the 
most commonly used since it is a scalable approach that avoids the use of organic solvents (Liu 50 
et al. 2011) which includes wet milling (Lee et al. 2010) and high pressure homogenization 
(Chen et al. 2008, Owen et al. 2009). The majority of the commercially available NP-based 
formulations such as Rapamune®, Emend®, TriCor®, Megace®, and Triglide® are produced using 
these techniques (van Eerdenbrugh et al. 2008). However, they are time and energy consuming 
methods (Shah 2006, Wiedmann et al. 1997, Yang et al. 2010, Tam et al. 2010). Moreover, the 55 
produced NPs are susceptible to contamination from milling media or the homogenization 
chamber (Chow et al. 2007).  
On the other hand, the bottom up approach is simple with relatively low cost and achieved 
mainly through antisolvent precipitation and solvent evaporation (Badawi et al. 2011, Weers et 
al. 2007). However, the application of bottom up techniques to industry is relatively challenging 60 
owing to the possible presence of organic solvent residues in the final product (Keck and Müller 
2006, Chen et al. 2006). Different solvent-antisolvent systems and stabilisers have been 
investigated for the production of ITR nanocrystals and amorphous NPs via antisolvent 
precipitation (Dalvi and Dave 2010, Matteucci et al. 2006, Kumar et al. 2009, Beck et al. 2010). 
Although nanocrystals exhibited an improved solubility and dissolution profile compared to the 65 
marketed product (Badawi et al. 2011), amorphous NPs are expected to have superior 
bioavailability due to the absence of a long-range order and periodicity in their structure (Shah 
et al. 2006). The formation of NPs involves several steps including supersaturation, nucleation 
and growth of the formed nuclei for nanocrystals, while supersaturation and precipitation is 
seen for amorphous NPs. Uncontrolled particle growth may result in the aggregation of NPs. 70 
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The size, solid state and purity of the produced particles mainly depend on the rate and degree 
of the generated supersaturation (Mullin and Nývlt 1971, Jones and Mullin 1974). A quasi-
emulsion solvent diffusion method was used by Re and Biscans (1998) to prepare ketoprofen 
microspheres using acetone as a solvent. Chen et al. (2002) introduced the use of antisolvent 
phase at high temperature (75 °C) to evaporate the solvent phase during antisolvent 75 
precipitation of NPs and this method resulted in the production of 253 nm cyclosporine NPs. 
The same method was utilised to produce ITR microparticles with rapid dissolution properties 
(Chen et al. 2004). To the best of our knowledge, no reports of ITZ NPs produced via this 
method are available in the literature. Bosselmann et al. (2012) demonstrated the production 
of partially amorphous ITR NPs using advanced evaporative precipitation in hot aqueous 80 
solution. The method employed in that study involved several steps and required pre-
emulsification of dichloromethane solution of ITR with lecithin in aqueous solution of PVP and 
sodium deoxycholate.  
In this work, we report on the use of a simple heat induced evaporative antisolvent 
nanoprecipitation (HIEAN) for the preparation of amorphous ITR NPs with and without a 85 
polymeric stabiliser. The effect of inclusion of poly(ethylene glycol) (PEG 2000) and its 
metoxylated derivative (MPEG) as stabilisers in the antisolvent phase was also investigated. The 
solid-state nature of the produced NPs was determined using thermal analysis and powder X-
ray diffraction. The effect of combining size reduction with the conversion into amorphous 
state on the solubility and dissolution profile of ITR in biorelevant media was examined. Finally, 90 
the properties of NPs and the effect of incorporation of PEG and MPEG as stabilisers were 
assessed using dynamic vapour sorption analysis. 
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2. Materials and methods 
2.1. Materials 
Itraconazole (ITR) was a gift from Welding GmbH (Hamburg, Germany). Poly(ethylene glycol) 95 
(PEG) and poly(ethylene glycol) methyl ether (MPEG) with average molecular weights of 2,000 
were purchased from Aldrich Chemical Co. Ltd. (Dorset, UK). Acetone Chromasolv® HPLC grade 
was obtained from Sigma-Aldrich (Dorset, UK). Acetonitrile HPLC grade was purchased from 
Fisher Scientific (Loughborough, UK). Simulated Intestinal Fluid (SIF) powder was acquired from 
Biorelevant.com Ltd (Croydon, Surrey, UK). Ethanol (≥99.8%) employed in DVS experiments was 100 
purchased from Sigma-Aldrich Ltd. (Arklow, Ireland). All other chemicals and solvents were of 
analytical grade.  
2.2. Heat induced evaporative antisolvent nanoprecipitation (HIEAN) of ITR 
The antisolvent phase was either pure deionised water or 0.64 mg/ml PEG (2,000) or 1 mg/ml 
MPEG (2,000) solution in deionised water and maintained at 80 °C. The solvent solution was 105 
prepared by dissolving 6.4 mg/ml of ITR in acetone and this solution was maintained at 50 °C. 
An aliquot of the solvent phase was rapidly injected into the antisolvent phase, that was 
continuously stirred at 13,000 rpm, using a 0.5 * 16 mm Sterican® needle using conditions 
(antisolvent phase and composition as well as solvent/antisolvent ratios) presented in Tables 1 
and 2. Once the whole volume of the ITR solution was injected, the mixture was immediately 110 
transferred to a jacketed cylinder and allowed to cool to 25 °C. 
2.3. Spray drying of amorphous microparticles of ITR 
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Amorphous microparticles (MPs) of ITR were prepared via spray drying using a laboratory scale 
Buchi B-290 mini Spray Dryer (Buchi LaboratoriumsTechnik AG, Flawil, Switzerland) operating in 
the open cycle mode configuration using nitrogen as a drying gas. 4% w/v ITR solution in 115 
dichloromethane was spray dried using the following parameters: inlet temperature of 40 °C, 
outlet temperature of 34 °C, atomising gas flow of 40 mm (rotameter setting) corresponding to 
473 normL/h, aspirator rate of 100% and a feed flow rate of 25% (10 ml/min). 
2.4. Determination of solubility of crystalline ITR 
Solubility of the crystalline ITR in acetone at different temperatures (0, 5, 10, 20, 30, 40, and 50 120 
°C) was determined as follows. At each temperature, 100 mg of ITR was added to 10 ml acetone 
kept in a closed vial and left to equilibrate overnight with a continuous stirring at 1,000 rpm. 
Each sample was then filtered through a 0.45 µm syringe filter (VWR, Ireland) and the filtrate 
diluted 200 times using the mobile phase (40% phosphate buffer and 60% acetonitrile v/v, as 
described in Section 2.5). Solubility of crystalline ITR in water and antisolvent solutions of 125 
different stabilisers (PEG 2,000 and MPEG 2,000) at 80 °C and 25 °C was also measured by 
equilibrating the drug in the antisolvent solution for 2 hours followed by filtration using a 0.45 
µm syringe filter (VWR, Ireland). For each sample, 1 ml of the filtrate was then evaporated in a 
microtube (VWR, Ireland), the residue was dissolved in 300 µl of the mobile phase and then 
analysed using HPLC (Section 2.5). 130 
Solubility of crystalline ITR in the fasted state simulated gastric fluid (FaSSGF, pH=1.6) and fed 
state simulated intestinal fluid (FaSSIF, pH=6.5) was assessed by placing 10 mg of the drug in 10 
ml of the simulated fluid (prepared according to manufacturer’s instructions) at 37 °C and in 
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each case the mixture was continuously stirred at 1,000 rpm. 2 ml aliquots were withdrawn 
from each vial after 12 and 24 hr and filtered through a 0.45 µm syringe filter. 0.6 ml of the 135 
filtrate was then diluted with 0.4 ml of the mobile phase and analysed using HPLC (Section 2.5).   
2.5. High performance liquid chromatography (HPLC) 
The concentrations of ITR were measured using a Waters Symmetry
®
 C18 5 µm (4.6*150 mm) 
column attached to a Waters HPLC system equipped with a Waters 1525 Binary HPLC pump, 
Waters 717 plus autosampler and operating with a Waters 2487 dual λ absorbance detector 140 
(λ=260 nm). For the solubility studies of ITR in acetone, a 50 µl injection volume was used with 
a flow rate of 2 ml/min for 7 min. For the solubility studies of ITR in the antisolvent phase a 100 
µl injection volume was used due to the low solubility of ITR in aqueous solutions. For the 
dissolution studies, 50 µl injection volumes were used with a flow rate of 1 ml/min for 14 min 
to prevent ITR peak from overlapping with peaks of the excipients present in the dissolution 145 
media. HPLC was also used to detect the quantity of ITR in the PEG and MPEG stabilised NPs 
and in those experiments a 20 µl injection volume was used.  
2.6. Separation, freeze drying and washing of ITR NPs 
The formed NP dispersions, as indicated later and except for the directly freeze dried sample 
(ITRf), were centrifuged at 12,000 rpm at 4 °C for 30 min using an Eppendorf 5810R centrifuge 150 
(Hamburg, Germany) (Badawi et al. 2011). The supernatant was removed and NPs in the pellet 
were frozen in liquid nitrogen and freeze dried at 35 mTorr vacuum pressure and -75 °C for 24 
hr using a VirTis Bench Top 6K freeze dryer model EL (SP Scientific, USA). The effect of washing 
on the NP morphology was studied by washing the residue left after centrifugation with 5 ml 
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deionised water. The suspension was then recentrifuged and freeze dried using the same 155 
conditions as mentioned above. Another sample was prepared and freeze dried without 
centrifugation to assess the necessity of this step.  
2.7. Characterisation of ITR particles 
2.7.1. Particle size and morphology 
The mean particle size and the polydispersity indices (PDI) of NPs were measured using 160 
Zetasizer Nano series (Malvern Instruments, UK). The samples were diluted 1:1 with the 
antisolvent solution and placed in a ZEN0112 low volume disposable sizing cuvettes. All 
measurements were carried out at 25 °C with an equilibration time of 2 min. The analysis was 
performed in triplicate for each sample and the average was recorded along with the PDI 
values. 165 
A Zeiss Supra variable Pressure Field Emission Scanning Electron Microscope (Germany) 
equipped with a secondary electron detector and accelerating voltage of 5 kV was used for the 
morphological examination of ITR particles. Aliquot samples of the nanosuspensions were 
placed directly on aluminium stubs and dried using nitrogen purge. For the freeze and spray 
dried samples, powders were placed on carbon tabs fitted on aluminium stubs. The solid 170 
samples were sputter coated with gold/palladium under vacuum before analysis. 
In an attempt to examine the surface texture of NPs in their native state before coating, helium 
ion microscopy (HeIM) was used where liquid samples were drop casted onto aluminium stubs, 
dried using nitrogen purge and examined using a Zeiss Orion plus (Peabody, MA, USA). All 
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images were acquired using 10 µm aperture and 30 kV accelerating voltage. Beam currents 175 
were 0.5 to 0.9 pA. No coating and no charge compensation techniques were used. 
2.7.2. Differential scanning calorimetry (DSC)  
Accurately weighed samples (7-9 mg) were placed in pin-holed aluminium pans. The DSC 
measurements were performed using a Mettler Toledo DSC 821e (Greifensee, Switzerland), 
under nitrogen purge. A temperature range of 25-200 °C was applied with a heating rate of 10 180 
°C/min (Liu et al. 2011). For the spray dried material a 5 °C/min heating rate was also used. The 
DSC system was controlled by Mettler Toledo STAR
e
 software (version 6.10). The starting ITR 
material, the stabilisers and physical mixtures were tested as reference samples. Integration 
under the crystallisation peak shoulder at around 120 °C (Δhcryst) and the melting endotherm at 
around 168 °C (Δhmelt) were utilised to estimate the percent crystallinity in the produced NPs 185 
using the following formula (Eqn. 1, Hancock and Parks 2000): 
%		

 = 
∆

     Eqn.1 
                       
 
where ΔhmeltITR is the heat of melting for pure crystalline ITR.  190 
 
2.7.3. Dynamic vapour sorption 
Spray dried ITR and ITR NPs were analysed with a Dynamic Vapour Sorption (DVS) Advantage-1 
automated gravimetric vapour sorption analyser (Surface Measurement Systems Ltd., London, 
UK). The temperature was maintained constant at 25.0 ± 0.1 °C (ethanol or water vapour) or 195 
50.0 ± 0.1 °C (water vapour). The analysis was performed in triplicate for each sample. In all 
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measurements, around 10 mg of the powder was loaded into a sample net basket and placed in 
the system. All samples were equilibrated at 0% of RH until constant mass (dm/dt ≤ 0.002 
mg/min for at least 10 min). The reference mass was recorded as a mass equilibrated at 0% RH. 
Samples were then subjected to either ethanol or water vapour sorption/desorption analysis in 200 
a range from 0% to 90% of relative pressure (P/P0) in 10% P/P0 steps.  
Samples recovered following the sorption-desorption cycle were analysed using PXRD and DSC 
to examine their solid-state properties and to detect the possible crystallisation of drug and/or 
polymer. 
2.7.4. Quantification of ITR in NPs (drug loading) 205 
HPLC (as described in Section 2.5) was used to quantify the amount of ITR in NPs. In these 
experiments, 1 mg of the produced NPs was dissolved in 10 ml of the phosphate 
buffer/acetonitrile mobile phase and analysed using HPLC. The stabiliser-free NPs were 
assumed to have 100% ITR since no stabilisers were used in the preparation of these NPs. 
2.7.5. Powder X-ray diffraction (PXRD) 210 
PXRD measurements were performed using a Rigaku Miniflex II, desktop X-ray diffractometer 
(Japan) equipped with a Cu Kα radiation X-ray source. The samples were mounted on a low-
background silicon sample holder and scanned over a 2θ range of 5-40° (Paluch et al. 2010).  
2.8. Determination of solubility of ITR nano- and micro-particles 
ITR displays pH dependent solubility and dissolution with a very low solubility at high pH (Miller 215 
et al. 2012), thus in this study the solubility of the produced NPs and the spray dried 
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microparticles were measured in pH 6.8 to assess any improvement in the solubility at high pH 
upon nanonisation. Simulated intestinal fluid (SIF, pH 6.8) was prepared according to the USP 
26
th
 edition (2003) and made of 6.805% w/v KH2PO4 and 0.896% w/v NaOH. The pH value of the 
medium was adjusted as necessary to pH 6.8 with 0.1 M NaOH. In each experiment, excess 220 
sample (25 mg) was added to 25 ml of the SIF placed in a temperature controlled jacketed 
cylinder, preheated to 37 °C and continuously stirred at 1,000 rpm. Sample aliquots (1 ml) were 
taken and filtered through a 0.1 µm membrane filter (Sartorius Stedim, Germany) at a 
predetermined time intervals for 4 hours and analysed with a Shimadzu Pharmspec UV-1700 
UV-Visible spectrophotometer at 262 nm without dilution using low volume 10-mm quartz 225 
cuvettes. The analysis was performed in triplicate for each sample and the average 
concentrations were plotted against time. 
The undissolved residues were examined using PXRD to assess possible crystallisation during 
solubility studies. 
2.9. Dissolution studies 230 
Dissolution profiles of the stabiliser-free, PEG and MPEG stabilised ITR NPs were compared to 
that of the spray dried ITR microparticles. From the solubility study, after 24 hr, the solubility of 
crystalline ITR in FaSSGF and FaSSIF was 2.36 and 0.26 µg/ml, respectively. Therefore, 10 mg of 
ITR NPs or microparticles (equivalent to approximately 42 times of the solubility of crystalline 
ITR in FaSSGF, similar to the studies of Matteucci et al. (2009)) were added to 100 ml of FaSSGF 235 
at 37 °C with a continuous stirring using an overhead paddle with a stirring rate of 100 rpm. 
Aliquots were withdrawn at 5, 10, 20, 30, and 60 min and filtered using 0.1 µm membrane 
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filters (Sartorius Stedim, Germany). An equal volume of FaSSGF was replaced except for the 60 
min sample were a concentrated solution of SIF, prepared based on an earlier experiment, was 
injected to shift the pH and the content of the dissolution media to that of FaSSIF and thus 240 
mimic the transition of the drug from the stomach to the small intestine. Following the pH shift, 
aliquots were withdrawn at 5, 10, 20, 30, 60, 120, and 180 min, filtered and an equal volume of 
FaSSIF was replaced. All filtered samples were diluted 3:2 v/v with the mobile phase and 
assayed using HPLC (Section 2.5). The analysis was performed in triplicate for each sample and 
the average was plotted against time. Dissolution data obtained was also used to evaluate the 245 
maximum concentration achieved, the time point at which this was achieved and the extent of 
supersaturation (AUC) as described before by Matteucci et al (2009). 
2.10. Statistical analysis 
Statistical analyses were performed via either a two sample t-test or one way ANOVA with the 
Tukey comparison test, as specified in relevant sections, using Minitab Release 16. For all tests, 250 
p ≤ 0.05 was used as the criterion to assess statistical significance. 
3. Results and discussion 
3.1. Solubility studies  
In this study, ITR NPs were precipitated from acetone using heat induced evaporative 
antisolvent technique (HIEAN). The particles were produced by injecting a volume of acetonic 255 
drug solution to a volume of water or an aqueous solution (antisolvent) kept at 80°C. The 
concentration of ITR in acetone used (6.4 mg/ml) was selected based on the solubility studies 
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conducted at different temperatures where the highest drug saturation was observed at 50 °C 
(7.34 ± 0.036 mg/ml). The concentration of the stabiliser in the antisolvent phase was chosen to 
be 10% relative to the drug concentration, similar to the conditions used by Liu et al. (2011). 260 
This concentration was observed here to provide the smallest particle size when PEG was used 
as a stabiliser and the particle size did not change significantly when this concentration was 
increased to 20% of the drug solubility. On the other hand, smaller particles were obtained as 
the concentration of MPEG in water was increased up to 1 mg/ml (Tables 1). Following this 
increase in MPEG concentration, there was no further size reduction observed. The solubility of 265 
crystalline ITR in the various antisolvent phases used in the HIEAN method elucidate that 
solubility of ITR in water at 80 °C and 25 °C was very similar and was below 0.5 µg/ml. The 
addition of PEG (0.64 mg/ml) and MPEG (1 mg/ml) to water increased the solubility of ITR with 
the 80 °C incubation temperature yielding higher solubilities (0.46 ± 0.001 and 0.61 ± 0.003 
µg/ml for the aqueous PEG and MPEG solutions, respectively) than those measured at 25 °C 270 
(0.38 ± 0.003 and 0.47 ± 0.006 µg/ml). The solvent injection volumes were chosen based on 
results summarised in Table 1 where the formulae has the suffix NPs. 
Table 1 summarises the experiments that were carried out to obtain NPs with smaller size and 
lower DPI values and shows that as the solvent/antisolvent ratio (v/v) increases (higher drug 
content is injected), larger and more polydispersed particles are produced. The 1:8 ratio v/v 275 
yielded particles in the nanometre range but they were larger than those produced when the 
1:10 ratio v/v was used and since a small difference in particle size is expected to have a 
considerable impact on solubility and dissolution (Kondo et al. 1993), the 1:10 
solvent/antisolvent (v/v) ratio was chosen. The successful production of NPs, especially the 
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stabiliser-free batch, can be explained with the aid of the precipitation steps described earlier 280 
and the acetone induced droplet formation reported by Re and Biscans (1998). Minute droplets 
are generated upon injecting the solvent phase into the antisolvent phase. This process of 
droplet formation is promoted by the mechanical shear forces of injection and mixing (Yang et 
al 2003). The very low solubility of ITR in water even at 80 °C resulting in the solidification of the 
droplet forming a shell enclosing the supersaturated solvent phase. The high temperature of 285 
the antisolvent permits rapid evaporation of the solvent (acetone) through the shell, 
solvent/antisolvent boundary, and thus the NPs are formed very quickly (Nocent et al 2001, 
Yang et al 2003). The rapid formation of NPs is suggested to prevent the assembly of drug 
molecules into the well-ordered crystal structure.  
3.2 Particle size and morphology 290 
The operating conditions used and the resulting mean particle sizes of the systems as measured 
by dynamic light scattering (DLS) are summarised in Table 2. The use of acetone at 50 °C as a 
solvent along with the use of 80 °C as the antisolvent temperature resulted in successful 
production of ITR NPs with mean particle sizes below 250 nm without the need of a stabiliser, 
thus ensures 100% drug loading, which, to the best of our knowledge, has not been reported 295 
before for ITR NPs. As it can be inferred from the SE micrographs, all produced NPs were 
spherical in shape with some of them displaying holes (Fig. 1a, b, c) which further supports the 
hypothesis of rapid solvent evaporation suggested earlier. The morphology of the NPs displayed 
in HeIM images was comparable to that from SEM, which excludes any artefacts due to the 
coating. The spray dried ITR particles were in the micron size range and possessed irregular 300 
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mushroom-like shapes as shown by SEM in Fig. 1d. The particles were highly polydisperse and 
could reach up to 10 µm in size. 
Based on the ANOVA test, the use of PEG as a stabiliser in the antisolvent phase had a 
statistically significant impact on the size of the produced NPs and enabled the production of 
less polydisperse NPs (Table 2). Liu et al. (2011) reported that PEG is not suitable for the 305 
production of ITR nanosuspensions using milling due to the absence of any hydrophobic groups 
which are required for the adsorption of the stabiliser on hydrophobic drugs such as ITR. 
Therefore, a more hydrophobic PEG derivative, methoxylated polyethylene glycol 2000 (MPEG 
2000), was used to assess any possible effects of slight chemical modification of the stabiliser 
on quality of produced nanoparticles. As it can be inferred from the DLS data (Table 2), the 310 
fabricated NPs had a relatively small mean particle size (although not significantly different in 
comparison to the PEG sample) but lower PDI compared to those produced with PEG, which is 
further confirmed by the SEM data (Fig. 1). It also indicates that although the solubility of ITR is 
higher in PEG and MPEG aqueous solutions (Table 1), the 1:10 solvent to antisolvent v/v ratio 
still provides the required supersaturation for the NP production.  315 
 
3.3 Impact of washing, centrifugation and freeze drying 
Impact of secondary NP treatment, such as washing, centrifugation and freeze drying, on 
morphology of NPs was assessed as these processes are often used in collection of NP-based 
products (Umerska et al. 2012). Table 4 presents the investigated sample handling. SE 320 
micrographs (Fig. 2a and b) of the non-washed, non-centrifuged but freeze dried sample (ITRf) 
illustrate micro- and nano-structures of different shapes with some hollow spheres (white 
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arrow) which are very close in shape to those obtained via spray drying of ITR/PEG6000/HPMC 
ternary dispersions (Janssens et al. 2008). Those non-uniform sample morphologies indicate 
that centrifugation is an essential step before freeze drying to collect the NPs. SE micrographs 325 
of the centrifuged samples illustrate that the shape and size of NPs did not exhibit any 
significant changes during freeze drying (Fig. 2c and d). Some of the freeze dried NPs were 
hollow and their surface exhibited pores, which is a common phenomenon associated with 
lyophilisation (Mukai et al. 2004, Wu et al. 2010). In addition, unwashed NPs showed a 
network-like arrangement following freeze drying (Fig. 2c, e and g), which was very close in 330 
morphology to the sample obtained by Yang et al. (2010) using ultra rapid freezing process with 
a ITR/mannitol solution. This network-like arrangement was not observed in the washed 
samples where intact and discreet NPs exhibiting better quality dominate the samples, which 
can be due to the removal of excess polymer and dissolved drug upon washing (Fig. 2d, f and h).  
3.4 Thermal analysis 335 
The thermal behaviour of the ITR NPs (without and with PEG or MPEG as stabilisers) as well as 
ITR:PEG (50:50 w/w) and ITR:MPEG (50:50 w/w) physical mixes is shown in Figure 3. The 
thermograms of the NPs were similar to that of the glassy ITR as described by Wang et al. 
(2004). The three NP samples exhibited a glass transition (Tg) event at approximately 60 °C, two 
endothermic transitions at 74 (TLC1) and 90 °C (TLC2) due to the formation of a chiral nematic 340 
mesophase (Six et al. 2001) and finally melting at ~168 °C. A crystallisation event (Tc) before 
melting was observable in the three samples at different temperatures. For the ITR only sample 
the crystallisation onset was at 105 °C and it shifted to higher temperatures in the stabilised 
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samples to 108 °C and 113 °C for ITR/PEG and ITR/MPEG NPs, respectively. The degree of ITR 
crystallinity in each sample was also calculated using Eqn. 1 and it was found that the stabiliser-345 
free sample had the highest degree of crystalline ITR of 24±1%, followed by the PEG stabilised 
sample with 22±1% crystalline ITR. MPEG stabilised sample had the lowest crystalline drug 
content with only 16±1% crystallinity. This difference in the degree of drug crystallinity in NPs 
may explain the shift of the crystallisation exotherm towards lower temperatures for the 100% 
ITR NP sample with the highest amount of crystalline material, which acts as nuclei that 350 
accelerate crystallisation of the amorphous fraction of the sample (Lefort et al. 2004). The spray 
dried microparticles were 100% amorphous and exhibited a similar thermal behaviour as NPs 
with a Tg at 60 °C followed by two endothermic transitions at 75 and 90 °C. The crystallisation 
event started at 125 °C and the melting endotherm at 168 °C. This melting endotherm was 
broader than that reported for the glassy itraconazole (Six et al. 2001) and those recorded for 355 
our NPs (Figure 3). Therefore, a second run with a heating rate of 5 °C/min was performed. 
With this heating rate it was possible to observe two peaks (with onsets at 161.0 and 167.6 °C). 
The peak at 161 °C may be due to melting of the less stable polymorph of ITR (Six et al. 2002, 
Werling et al. 2007), which formed during crystallisation of amorphous, spray dried ITR. Such a 
peak was not detected in any of the DSC thermograms of ITR NPs, which indicates that although 360 
both microparticles and nanoparticles were liquid crystalline, their thermal behaviour was 
different. The second peak (at 167.6 °C) was the melting peak of the stable polymorph of ITR, as 
seen for NPs.   
3.5 PXRD analysis 
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The diffractogram of the starting ITR material was characterised by sharp Bragg peaks, which 365 
confirm its crystalline structure. PXRD patterns obtained for all ITR NPs, with and without a 
stabiliser, revealed the presence of a single liquid crystal peak at 6.05 2θ degrees and absence 
of the characteristic peaks of crystalline ITR, thus confirming their disordered nature. No 
diffraction peaks for the polymers were detected. This was consistent with DSC data revealing 
either no detectable quantity of polymers bound to ITR or the presence of these polymers in an 370 
amorphous form. The first hypothesis can be excluded based on HPLC data, which proves that 
ITR/PEG and ITR/MPEG NP samples are not 100% ITR (drug loading of 93.91 ± 0.12 and 92.4 ± 
0.47% for ITR/PEG and ITR/MPEG NPs, respectively). This suggests that both polymers were 
present in the amorphous form in the stabilised NPs, which was further assessed by the DSC 
analysis of the samples obtained following exposure to ethanol and water vapour in DVS 375 
(Section 3.8). 
3.6 Determination of NP solubility  
Solubility studies performed for 4 hours demonstrated that the three NP samples: the 
stabiliser-free and the polymer stabilised, provided higher amounts of solubilised ITR than the 
spray dried microparticles. MPEG stabilised NPs showed higher apparent solubility with about 380 
20% more ITR soluble compared to the PEG stabilised NPs in the first 10 minutes and reached a 
steady state of 1.45 ± 0.02 µg/ml after 3 hours (Figure 5). PEG stabilised NPs showed a very 
close solubility profile to that of their MPEG stabilised counterparts in the first hour although 
they reached a steady state at lower concentrations of 1.08 ± 0.02 µg/ml after 3 hours. This can 
be attributed to the fact that MPEG has an OH group methoxylated which render the polymer 385 
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more hydrophobic compared to PEG, thus of a greater affinity to ITR. In addition, these NPs had 
a higher polymer content (Table 3). This higher percentage of polymer may have also resulted 
in an improved wetting of NPs. The solubility profile of the 100% ITR NPs was not far from those 
of the PEG and MPEG stabilised NPs in the first hour, however a lower (in comparison to the 
polymer containing NPs) steady state concentration of 0.79 ± 0.01 µg/ml after 3 hours was 390 
attained. In contrast, spray dried microparticles had a different solubility profile where there 
was a slower increase in solubility beyond 30 minutes than those observed for the NPs with a 
lower steady state concentration (0.54 ± 0.04 µg/ml). This superior behaviour of NPs produced 
using HIEAN method compared to the fully amorphous microparticles is owing to the 
combination of the advantages of the amorphous nature with the nanosize which led to an 395 
increase in the drug apparent solubility.  
PXRD patterns obtained for the undissolved NPs that remained after the solubility studies (Fig. 
6) revealed that the ITR NPs without the polymeric stabiliser had a very weak tendency to 
crystallise during the experiments since they produced the characteristic halo of an amorphous 
material with very low intensity Bragg peaks. On the other hand, the polymer (PEG or MPEG) 400 
stabilised NPs ITR had a greater tendency to crystallise as shown in Figure 6. This can be due the 
higher solubility of the stabilised NPs, which is due to the presence of the polymer.  
3.7. Dissolution studies 
ITR NPs produced using HEIAN method showed significant superiority over the spray dried 
microparticles during solubility investigation in high pH and dissolution studies were conducted 405 
to assess the effect of this behaviour on the dissolution properties of ITR mimicking GIT 
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conditions. The saturation solubility of crystalline ITR in FaSSGF is approximately 2.36 ± 0.003 
µg/ml. The dissolution profile of MPEG stabilised NPs illustrates a slow release of ITR from the 
formulation in the first 30 minutes in FaSSGF followed by a steep increase in the dissolved ITR 
until a peak of 11.6 ± 0.5 µg/ml (~ 5 times solubility of crystalline ITR) is reached after 60 410 
minutes (Figure 7). The slow release of ITR in the first 30 minutes was in accordance with the 
visual monitoring of the dissolution process (powder was floating on the surface for the first 30 
minutes of the study) where the mixing speed of the paddle was not sufficient to wet the ITR 
NPs instantly. Following the pH shift, the large quantity of solubilised ITR was responsible for 
the sudden drop of ITR concentration in FaSSIF after 5 minutes due to the low saturation 415 
solubility of ITR in FaSSIF (approximately 0.26 ± 0.001 µg/ml). This low saturation solubility is 
the driving force for nucleation and growth via coagulation as described by Matteucci et al. 
(2009). The drop in concentration of ITR in the dissolution medium continued until the 
dissolved ITR reached 2.3 ± 0.2 µg/ml after 3 hours in FaSSIF, which is most likely to be due to 
the crystallisation of some ITR as demonstrated during the solubility study. PEG stabilised NPs 420 
yielded a peak concentration of 3.7 ± 0.7 µg/ml after 5 minutes following the switch of the 
dissolution media to FaSSIF (although pH of the media increased). This peak was followed by a 
decrease in ITR level to 2.1 ± 0.03 µg/ml, about 8 times solubility in FaSSIF, within 60 minutes. 
ITR only NPs exhibited a dissolution profile closely resembling that of PEG stabilised ITR NPs 
with a peak concentration of 2.6 ± 0.3 µg/ml achieved 5 minutes following the media pH shift. 425 
The results indicate that the absence of high supersaturation before shifting the media along 
with the presence of excipients in FaSSIF, compared to the MPEG stabilised NPs, prevents 
sudden drug precipitation following pH shift and enables to sustain the high apparent solubility 
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of ITR in pH=6.5. In addition, the relatively high levels of dissolved ITR from the stabilised NPs 
compared to the stabiliser-free NPs in the FaSSGF support the hypothesis of amorphous drug 430 
present along with amorphous polymer on the surface of the NPs. This amorphous ITR is 
wetted and dissolved in FaSSGF yielding 1.4 ± 0.01 and 1.2 ± 0.09 µg/ml of ITR in the first 30 
minutes from the MPEG and PEG stabilised NPs, respectively. Spray dried microparticles 
exhibited the lowest peak maximum (0.4 ± 0.01 µg/ml) 5 minutes following pH shift. This 
indicates that size reduction and thus an increase in powder surface area had a greater effect 435 
on dissolution properties of ITR in comparison to the solid state effects as the MPs were fully 
amorphous compared to the NPs (Leuner et al. 2000). A decrease in ITR concentration to 0.14 ± 
0.02 µg/ml occurred within 60 minutes for ITR MPs following pH shift to 6.5. This can be 
explained by the partial crystallisation observed from the PXRD analysis of the undissolved 
microparticles remained following solubility study.  440 
To get an insight into the total amount of ITR released throughout the dissolution study, the 
area under the curve (AUC) for each of the four samples was calculated and the results, along 
with maximum concentration achieved, expressed here as Cmax for lucidity, are presented in 
Table 5. A two sample t-test was also carried out for AUC and Cmax. From the AUC data it can be 
inferred that the soluble ITR available in the dissolution media from the MPEG stabilised NPs 445 
was twice that of the PEG stabilised batch. The polymer-free NPs and the spray dried 
microparticles provided considerably less soluble ITR. The effect of size reduction is 
demonstrated by the higher AUC of the stabiliser-free NPs compared to the MPs. However, the 
presence of a small quantity of polymer has a greater implication on the solubility than does 
the size only as indicated by the approximately twelve fold greater AUC of the MPEG stabilised 450 
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NPs compared to their stabiliser-free counterparts. Statistical analysis indicates that all AUC and 
Cmax values calculated for all the samples were statistically significantly different. The type of 
the polymer included had a significant impact on the behaviour of the NPs in the dissolution 
studies as can be inferred from the improvement in AUC and Cmax associated with the exchange 
of PEG by MPEG in the NPs, although there was no significant difference in the size of the 455 
produced NPs as indicated earlier (Table 2).    
3.8. Dynamic vapour sorption 
In Figure 8, DVS isotherms of a full cycle of sorption-desorption of the spray dried amorphous 
ITR and the ITR NPs in ethanol vapour are displayed. The isotherms revealed that the spray 
dried amorphous ITR (MPs), when exposed to a series of 10% step changes of ethanol vapour 460 
from 0 to 90% P/P0, gained a mass of 4.29 ± 0.21% of its dry weight up to 80% P/P0 followed by 
a mass loss of 3.66 ± 0.35% in the 80-90% P/P0 step. A lower mass gain, 3.41 ± 0.13% at 70% 
ethanol vapour in the sorption cycle, was showed by the ITR NPs produced using the HEIAN 
method, which indicates that they are less stable than the spray dried powder. Another mass 
gain of 0.16 ± 0.03% occurred by the end of the sorption cycle (between 80 and 90% P/P0). The 465 
PEG and the MPEG stabilised NPs were characterised by a mass gain of 2.73 ± 0.12 and 2.53 ± 
0.07% up to 60% P/P0, respectively, followed by a mass loss (2.16 ± 0.08 and 1.61 ± 0.13%) in 
the 60-70% ethanol vapour step.  
According to DVS data, the spray dried ITR sorbed more ethanol vapour than the other samples 
because it was a fully amorphous material unlike the NPs produced by the HIEAN method 470 
where the crystalline content could act as nuclei for crystallisation. Among the NPs, although 
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they are less amorphous based on DSC data, the stabiliser-free NPs absorbed more ethanolic 
vapour than did the polymer stabilised NPs. This could be because the latter contain either PEG 
or MPEG, which also attract the ethanol vapour. All samples were fully crystalline after one 
sorption-desorption cycle upon examination by PXRD and DSC, where the characteristics 475 
crystalline ITR PXRD patterns and the sharp endotherm at 168 °C in DSC thermograms were 
observed. In the polymer stabilised samples there was a small endotherm observed at 52 °C, 
which is most likely the characteristic melting peak of PEG or MPEG. This supports the 
hypothesis (stated earlier in Section 3.5) of the presence of amorphous polymers in the NPs, 
which crystallised upon exposure to ethanol vapour. 480 
The moisture sorption-desorption isotherms using water vapour for the ITR NPs at 25 and 50 °C 
are illustrated in Figure 9 a, b, and c.  All isotherms at 25 °C have a hysteresis, where the water 
content at each relative humidity step is higher during desorption than sorption. The 
condensed water on the surface can act as a driving force for water penetration which is not 
applicable for desorption (York 1981). In addition, in the PEG and MPEG stabilised NPs, the 485 
presence of a small quantity of the hygroscopic polymer can also attract more water during the 
sorption cycle and retain it during the desorption, which makes a greater hysteresis effect in 
isotherms of the stabilised NPs. This also explains the higher water uptake (mass gain) observed 
in the polymer stabilised NPs (2.63% and 2.59% for ITR/PEG and ITR/MPEG at 90% RH, 
respectively) compared to 2.00% for the polymer-free NPs. The effect of the hygroscopic 490 
polymer can be also inferred from the final weight of the sample after the sorption/desorption 
cycle, which is higher than that of the initial sample mass in the case of the polymer stabilised 
NPs, where the polymer retained a higher quantity of water compared to the polymer-free NPs, 
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where no observable weight gain was found at the end of the desorption cycle. There were no 
pores observed in the SE micrograph of the spray dried sample (Fig. 1) and this, in combination 495 
with the lower surface area of MPs, might explain the lower hysteresis effect compared to that 
of the NPs (Columbano et al. 2002). The total mass gain (water uptake) was also lower in the 
spray dried sample, 1.8% at 90% RH.   
The moisture sorption and desorption isotherms generated with water vapour at 50 °C were 
type III isotherm according to the IUPAC system (Airaksinen et al. 2005) and characteristic of a 500 
weak adsorbate-adsorbent interaction which is consistent with the hydrophobic nature of ITR. 
The isotherms illustrate mass gains in all samples due to water uptake (Figure 9). The 
percentage of mass gain was different for each sample. In general, NPs exhibited lower mass 
gains compared to MPs. The maximum uptake among the NPs was by the PEG stabilised 
sample, which was also characterised by the highest uptake at 25 °C (squares in Figure 9). In 505 
addition, there was a very small hysteresis effect observed all of the isotherms obtained for the 
NP samples indicating that water sorption under these conditions was completely reversible, 
which can be attributed to analysis of the samples at 50 °C, which may facilitate water 
evaporation during desorption. Unlike the 25 °C data, the 50 °C isotherms of MPs indicate the 
highest weight gain in comparison to all samples investigated (about 2.49 ± 0.04 % of its dry 510 
weight at 90% RH).  
DSC and PXRD examination of all samples subjected to water vapour showed that all samples 
were still amorphous following exposure to water vapour at 25 °C in DVS. A slight shift in the 
crystallisation exothermic peak temperature in DSC was observed for all samples. The MPEG 
stabilised sample, which appeared to have the highest crystallisation temperature was found to 515 
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have the lowest crystallisation onset following DVS analysis (94 ± 0.3 °C), followed by the PEG 
stabilised NPs which crystallised at 98.9 ± 0.1 °C (onset). In both samples a melting peak at 52 °C 
was observed due to crystallised polymer. The stabiliser-free sample was the most stable 
among the NP samples and crystallised at 104.2 ± 0.3 °C (onset). The spray dried MPs were less 
affected by the exposure to water vapour at 25 °C in DVS and crystallisation started at 125.2 ± 520 
0.3 °C. The above observations illustrate the effect of polymer crystallisation on thermal 
stability of the NPs, where the entrapment of water and rearrangement of polymer molecules 
facilitate ITR crystallisation at lower temperatures compared to the polymer-free samples. 
Similarly, all samples exhibited the halo pattern with a single liquid crystal peak upon 
examination using PXRD, consistent with DSC data. 525 
Upon elevation of the DVS analysis temperature to 50 °C, a further decrease in the 
crystallisation onset temperature was recorded for all nanoparticulate samples (ITR NPs = 97.9 
± 0.4, ITR/PEG NPs = 97.1 ± 0.5, ITR/MPEG = 93.2 ± 0.7 °C). On the other hand, when examined 
by PXRD, in the polymer stabilised NPs there were some residual peaks emerging from the halo 
pattern along with the single liquid crystal peak, which further explains the crystallisation peak 530 
shift to lower temperatures in DSC. These residual crystalline peaks where hardly detected in 
the stabiliser-free NPs and the spray dried microparticles. On the other hand, the liquid crystal 
peak was nearly invisible in the diffractogram of microparticles, which could indicate a phase 
change. DSC thermogram showed a crystallisation onset at a lower temperature, 120.1 ± 0.3 °C 
of the DVS sample compared to 125 ± 0.9 °C for the untreated ITR MPs and the enthalpy of 535 
melting of the metastable polymorph was slightly greater than that of the material before DVS 
experiment. Collectively, observations from DVS at 50 °C, DSC and PXRD suggest a possible 
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structural collapse in part of the amorphous MP sample during the DVS cycle. Structural 
collapse before crystallisation was reported by Buckton and Darcy (1996), where exposure to 
40% and 50% RH induced structural changes but not crystallisation of lactose. 540 
4. Conclusions 
The heat induced evaporative antisolvent nanoprecipitation (HIEAN) of ITR from acetone at 80 
°C produces primarily amorphous NPs with the mean particle size less than 250 nm and 100% 
drug loading. These NPs demonstrated greater solubility and improved dissolution profile 
compared to the spray dried amorphous ITR microparticles. Smaller NPs with lower 545 
polydispersity indices can be obtained when polyethylene glycol or its methoxylated derivative 
is included in the antisolvent phase as a stabiliser. Enhanced dissolution was associated with 
the use of MPEG as a stabiliser. In all samples, washing appears to improve the quality of the 
produced NPs. Centrifugation was found to be an essential step for the collection of NPs, 
otherwise a mixture of particles with different shapes and sizes were obtained. The stabilising 550 
polymer was in an amorphous state as evidenced by PXRD, DSC and DVS studies. Analysis 
indicates that there was no significant change in the solid state properties of ITR NPs when 
subjected to water vapour up to 90% RH at 25 °C with an increase in the crystallinity in the 
polymer stabilised samples if temperature was increased to 50 °C.   
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Table 1. Outline of trial experiments, which were done to optimise the precipitation 
conditions and the size of NPs. PDI – polydispersity index, SD – standard deviation. 
Formula 
PEG conc. 
(mg/ml) 
MPEG 
conc. 
(mg/ml) 
Solvent/antisolvent 
(v/v) ratio 
Mean particle 
size ± SD (nm) 
PDI ± SD 
ITR only 0 0 1:8 797 ± 56 0.053 ± 0.040 
ITR only 0 0 1:6.7 1489 ± 168 0.156 ± 0.078 
ITR only 0 0 1:5 1708 ± 423 0.782 ± 0.377 
ITR only NPs* 0 0 1:10 240 ± 3 0.087 ± 0.014 
ITR PEG 0.64 0 1:8 780 ± 52 0.174 ± 0.042 
ITR PEG 0.64 0 1:6.7 1169 ± 195 0.221 ± 0.078 
ITR PEG 0.64 0 1:5 1539 ± 337 0.290 ± 0.170 
ITR PEG NPs* 0.64 0 1:10 221 ± 2 0.041 ± 0.007 
ITR PEG 1.00 0 1:10 222 ± 3 0.038 ± 0.011 
ITR MPEG 0 0.64 1:10 220± 4 0.048 ± 0.025 
ITR MPEG 0 0.64 1:8 378 ± 19 0.106 ± 0.054 
ITR MPEG 0 0.64 1:6.7 609 ± 108 0.174 ± 0.038 
ITR MPEG 0 0.64 1:5 794 ± 129 0.388 ± 0.237 
ITR MPEG 
NPs* 
0 1.00 1:10 216 ± 0.4 0.011 ± 0.007 
* - final formulations selected for further testing  
  
Table 2. Manufacturing and separation conditions employed to optimise the quality of 
produced particles. In all cases the solvent and antisolvent temperatures were 50 and 80 °C, 
respectively, and a 1:10 solvent/antisolvent (v/v) ratio was used. 
Sample 
Stabiliser 
conc. 
(mg/ml) 
Stabiliser 
phase 
Centrifugation Washing 
Freeze 
drying 
ITRf N/A N/A No No Yes 
ITRcf N/A N/A Yes No Yes 
ITRwcf N/A N/A Yes Yes Yes 
ITR/PEGcf 0.64 Antisolvent Yes No Yes 
ITR/PEGwcf 0.64 Antisolvent Yes Yes Yes 
ITR/MPEGcf 1.00 Antisolvent Yes No Yes 
ITR/MPEGwcf 1.00 Antisolvent Yes Yes Yes 
 
  
Table 3. Summary of the EOS (extent of supersaturation), Cmax (maximum concentration), 
Tmax (time to maximum concentration) parameters obtained from the dissolution studies. SD 
– standard deviation. 
Sample 
EOS0-240min ± SD 
(µg·min/ml) 
Cmax ± SD 
(µg/ml) 
ITR NPs 68.0 ± 2.9 2.6 ± 0.3 
ITR/PEG NPs 469.2 ± 7.6 3.7 ± 0.7 
ITR/MPEG NPs 843.1 ± 24.6 11.6 ± 0.5 
SD MPs 30.7 ± 3.6 0.4 ± 0.01 
 
   
 
Figure 1. SE micrographs and HeI micrographs (in the upper left corner of SE micrographs 
for NPs) of: (a) stabiliser-free ITR NPs, (b) PEG stabilised NPs, (c) MPEG stabilised NPs and (d) 
spray dried ITR microparticles. 
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Figure 2. Scanning electron micrographs of (a, b) ITRf NPs (c) ITRcf NPs, (d) ITRwcf NPs, (e) 
ITR/PEGcf NPs (f) ITR/PEGwcf NPs, (g) ITR/MPEGcf NPs and (h) ITR/MPEGwcf NPs. White 
arrow shows an apparent hole in the nanoparticle, sample codes are explained in Table 4.  
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 Figure 3. DSC thermograms of: (a) spray dried ITR MPs, (b) stabiliser-free ITR NPs, (c) PEG 
stabilised NPs, (d) MPEG stabilised NPs, (e) ITR and PEG 50:50 (w/w) physical mix and (f) ITR 
and MPEG 50:50 (w/w) physical mix. Tg – glass transition, TLC1 and TLC2 – events associated 
with liquid crystalline transitions and TC – onset of crystallisation.  
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Figure 4. PXRD diffraction patterns of (a) crystalline ITR, (b) spray dried microparticles, (c) 
stabiliser-free ITR NPs, (d) PEG stabilised NPs, (e) MPEG stabilised NPs, (f) crystalline PEG 
and (g) crystalline MPEG. 
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 Figure 5. Solubility profiles of (a) spray dried microparticles, (b) stabiliser-free ITR NPs, (c) 
PEG stabilised NPs and (d) MPEG stabilised NPs. 
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Figure 6. PXRD patterns of the remaining undissolved powders following solubility studies of 
(a) spray dried microparticles, (b) stabiliser-free ITR NPs, (c) PEG stabilised NPs and (d) 
MPEG stabilised NPs. 
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 Figure 7. Dissolution profiles of ITR nano- and micro-particles. The vertical line indicates 
dissolution media change from FaSSGF to FaSSIF.  
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Figure 8. DVS sorption-desorption isotherm of (a) stabiliser-free ITR NPs, (b) PEG stabilised 
ITR NPs, (c) MPEG stabilised ITR NPs, and (d) spray dried ITR MPs. Experiments were carried 
out at 25 °C using ethanol.  
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Figure 9. DVS sorption-desorption isotherm of (a) stabiliser-free ITR NPs, (b) PEG stabilised 
ITR NPs (c) MPEG stabilised ITR NPs and (d) SD ITR MPs. Experiments were carried out at 25 
and 50 °C using water. 
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